Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Social Media Use During COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04305574
Recruitment Status : Recruiting
First Posted : March 12, 2020
Last Update Posted : March 17, 2020
Sponsor:
Information provided by (Responsible Party):
Jean Liu, Yale-NUS College

Brief Summary:
The investigators plan to conduct a cross-sectional survey to examine how social media use during COVID-19 relates to: (1) information management, (2) assessment of the situation, and (3) affect.

Condition or disease Intervention/treatment
Coronavirus Depression Anxiety Stress Behavioral: Use of social media during COVID-19

Layout table for study information
Study Type : Observational
Estimated Enrollment : 5000 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Getting it Right: Towards Responsible Social Media Use During a Pandemic
Actual Study Start Date : March 8, 2020
Estimated Primary Completion Date : May 31, 2020
Estimated Study Completion Date : May 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Group/Cohort Intervention/treatment
Community sample
We plan to recruit a representative sample of the Singapore population.
Behavioral: Use of social media during COVID-19
Participants' self-reported use of social media to receive and share news about COVID-19




Primary Outcome Measures :
  1. Assessment of COVID-19 situation [ Time Frame: Single measurement (upon study enrolment) ]
    3 items on fear of the situation, confidence the government can manage the situation, and assessed chance of being infected (each rated using 4-point scales: min = 1, max = 4; higher scores indicate increased confidence / likelihood / fear)

  2. Depression, Anxiety and Stress Scale [ Time Frame: Single measurement (upon study enrolment) ]
    21-item validated scale assessing symptoms of depression, anxiety, and stress (DASS-21): Min score = 0, Max score = 21; higher score indicates a worse outcome


Secondary Outcome Measures :
  1. Familiarity and trust in COVID-related rumours [ Time Frame: Single measurement (upon study enrolment) ]
    Participants' self-report of their familiarity (yes/no) and belief of specific (yes/no), and whether they shared these on social media (yes/no)

  2. Availability heuristic [ Time Frame: Single measurement (upon study enrolment) ]
    Participants' assessment of how many cases there have been in COVID-19 and SARS



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Representative sample of the Singapore population
Criteria

Inclusion Criteria:

  • At least 21 years
  • Has stayed in Singapore for at least 2 years

Exclusion Criteria:

  • Below 21 years
  • Has stayed in Singapore for less than 2 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04305574


Contacts
Layout table for location contacts
Contact: Jean Liu, PhD 66013694 jeanliu@yale-nus.edu.sg

Locations
Layout table for location information
Singapore
Yale-NUS College Recruiting
Singapore, Singapore, 138527
Contact: Jean Liu, PhD       jeanliu@yale-nus.edu.sg   
Sponsors and Collaborators
Jean Liu
Investigators
Layout table for investigator information
Principal Investigator: Jean Liu, PhD Yale-NUS College
Layout table for additonal information
Responsible Party: Jean Liu, Assistant Professor, Yale-NUS College
ClinicalTrials.gov Identifier: NCT04305574    
Other Study ID Numbers: 2020-CERC-001
First Posted: March 12, 2020    Key Record Dates
Last Update Posted: March 17, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Due to stipulations by the Institutional Review Board, data cannot be shared.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jean Liu, Yale-NUS College:
COVID-19
Social media
Communication
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Depression
Behavioral Symptoms
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases